SOCMA Supports Efforts To Reform Toxic Substances Control Act
In a statement regarding the introduction of the ‘Safe Chemicals Act of 2010’ in the US Senate, Frank Lautenberg, US Senator, said: “SOCMA supports efforts to promote the
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
Protein Potential’s R&D program is focused on vaccine development. The company has ongoing projects targeting vaccines for infectious diseases like malaria and bioterrorism agents including anthrax. Protein Potential’s
Perrigo is a global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. Analpram HC Cream